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ObjectiveaaGlycogen synthase kinase-3β (GSK-3β) has become recognized as a broadly influential enzyme affecting diverse range of bi-
ological functions, including gene expression, cellular architecture, and apoptosis. The results of previous studies suggest that GSK-3β ac-
tivity may be increased in the brain of patients with major depressive disorders (MDD). A recent animal study reported increased GSK-
3β messenger ribonucleic acid (mRNA) level in the hippocampus of those with depression. However, few studies have investigated GSK-
3β activity in the brain of patients with MDD.
MethodsaaIn order to test whether patients with MDD have an increase in GSK-3β activity in the brain compared to normal controls, we 
explored GSK-3β expression level in all brain regions by using the Stanley Neuropathology Consortium Integrative Database (SNCID), 
which is a web-based method of integrating the Stanley Medical Research Institute data sets. 
ResultsaaThe level of GSK-3β mRNA expression in the hippocampus was significantly increased in the MDD group (n=8) compared with 
the control group (n=12, p<0.05). Spearman’s test also reveals that GSK-3β mRNA expression levels were significantly correlated with nitric 
oxide synthase 1 (NOS1)(ρ=0.70, p<0.0001) and stathmin-like 3 (STMN3)(ρ=0.70, p<0.0001) in the hippocampus.
ConclusionaaOur results correspond with the results of previous animal studies that reported increased GSK-3β activity in the hippocam-
pus of those with depression. Our findings also suggest that oxidative stress-induced neuronal cell death and abnormal synaptic plasticity 
in the hippocampus may play important roles in the pathophysiology of major depression.  Psychiatry Investig 2010;7:202-207
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INTRODUCTION
Glycogen synthase kinase-3 (GSK-3) was first identified as 
a protein kinase that phosphorylates and inhibits glycogen 
synthase.
1 GSK-3 exists in two closely related isoforms, GSK-3α 
and GSK-3β. GSK-3β is an important regulatory protein involv-
ed in many intracellular signaling pathways leading to neural 
plasticity adaptations and influencing cell survival.
2 Overex-
pression of GSK-3β in neurons increased neuronal apoptosis.
3
In psychiatry, GSK-3β has been highlighted by the discov-
ery of its inhibition by lithium, one of the most effective drugs 
for the treatment of bipolar disorder.
4 Recently, two animal 
studies in 2004 demonstrated that rats treated with GSK-3 in-
hibitors showed reduced duration of immobility when exposed 
to the forced swim test and suggested the potential of GSK-3 
inhibitors as antidepressants.
5,6 GSK-3β activity would be also 
associated with serotonergic regulation which is closely relat-
ed with mood disorder. Stimulation of 5HT1A receptors caus-
ed phosphorylation (inactivation) of GSK-3β, whereas 5HT2 
receptor stimulation mediated dephosphorylation (activation) 
of GSK-3β.
7
Several previous studies suggest that GSK-3β may be asso-
ciated with the pathophysiology of major depressive disorders 
(MDD). A human post-mortem study indicated that GSK-3β 
activity of the ventral prefrontal cortex was increased in pa-
tients with major depression compared with control subjects.
8 
A genetic study showed GSK-3β genetic variants play a role in 
online © ML CommDH Oh et al. 
   www.psychiatryinvestigation.org  203
the antidepressant therapeutic response.
9 Reduced gray mat-
ter volume in the right hippocampus and bilateral superior 
temporal gyrus is related with a common intronic polymorph-
ism (rs6438552) at the GSK-3β locus in patients with MDD.
10
In animal studies, mild traumatic brain injury (mTBI) re-
sulted in depressive behavior and increased phosphorylation 
of inhibitory site serine 9 of GSK-3β in the hippocampus of 
the rat. Pretreatment with GSK-3 inhibitors prevented mTBI-
induced depression.
11 A chronic mild stress model induced de-
pressive-like behavior that was paralleled by hypercortisolemia 
and an increase of GSK-3β messenger ribonucleic acid (mRNA) 
expression in the hippocampus.
12
However, there are few reports that have investigated the 
GSK-3β level in the brain of patients with MDD. We hypothe-
sized that patients with MDD have an increased level of GSK-
3β in the brain compared to that of normal controls. In order 
to test this hypothesis, we explored a specific marker type (GSK-
3β) in all brain regions by using the Stanley Neuropathology 
Consortium Integrative Database (SNCID)(http://sncid.stan-
leyresearch.org/) which is a web-based tool to integrate the St-
anley Medical Research Institute (SMRI) data sets. We also at-
tempted to identify which markers correlate with GSK-3β levels 
in a specific brain region.
METHODS
Post-mortem brain tissues
The SNC is a subset of 60 specimens from the collection, 
well-matched groups of 15 each with diagnoses of schizophre-
nia, bipolar disorder, MDD without psychotic features, and 
normal controls. Diagnoses were made independently by two 
senior psychiatrists according to DSM-IV. The four groups are 
matched by age, sex, race, postmortem interval (PMI), brain 
pH, side of brain, and mRNA quality. Specimens are collected 
with the permission of the families in a standardized man-
ner, with half of each specimen being frozen and half fixed in 
formalin. 
More than 75,000 sections and blocks from the Consortium 
have been sent to over 50 research groups worldwide to carry 
out a wide variety of assessments. The details of the sample 
collection have been reported previously.
13
Stanley Neuropathology Consortium Integrative 
Database
The SNCID has been generated with multiple datasets from 
research groups located all over the world. Research is still be-
ing conducted with SNC tissue, and data sets are continually 
being returned to the SMRI. Hence, this SNCID will continue 
to be updated. The SNCID is freely available to all users. How-
ever, for commercial use, agreement and permission should 
be obtained from the SMRI. Descriptive statistical and vari-
ance analysis modules (R-scripts) enable users to identify neu-
ropathological traits in multiple brain areas for psychiatric dis-
orders such as bipolar disorder, depression and schizophrenia.
Statistical analysis
The effect of the disorders on the neuropathology markers 
(such as GSK-3β) was initially tested by variance analysis. The 
nonparametric Kruskal-Wallis test was used because not all of 
the traits are normally distributed. If there was a significant ef-
fect of the disorders on a trait (p<0.05), a post hoc Mann-Whit-
ney U-test for group differences between each disorder group 
and unaffected controls was used (R-packages, http://www.r-
project.org/). In order to determine which markers correlate 
with GSK-3β in specific brain regions, the Spearman’s rank cor-
relation test was performed.
14 
To examine whether the neuropathology marker was affect-
ed by age, brain pH, duration of illness, lifetime exposure to 
antipsychotics and PMI, we determined their interrelation-
ships by Spearman’s correlation analysis. The effect of categor-
ical variables (such as sex, smoking, suicide, psychotic feature, 
alcohol, and drug abuse) on the neuropathology markers was 
also tested by nonparametric variance analysis. p-values less 
than 0.05 were considered significant. Using analysis of cova-
riance (ANCOVA) or partial correlation analysis, the effect of 
the neuropathology marker is estimated after controlling for 
the effect of confounding variables.
For this study, we also downloaded the raw data from the 
SNCID website (repository database) for confirming online st-
atistical results and further statistical analysis by using the 
Statistical Package for the Social Sciences (SPSS) 17.0 software 
(SPSS Inc., Chicago, IL, USA).
RESULTS
In the SNCID, we found 3 studies which investigated GSK-
3β expression in the brain regions (Table 1). Among them, 
when we confirmed the results of variance analysis in all three 
studies, we found William Deakin’s study showed statistically 
significant results. Namely, GSK-3β mRNA expression in the 
hippocampus only showed significant findings in the variance 
analysis. 
The variance analysis of GSK-3β mRNA expression 
in the hippocampus
The results of the variance analysis are summarized in Table 
2. The level of GSK-3β mRNA expression in the hippocampus 
was significantly increased in the MDD group (n=8, 0.014± 
0.004) compared with the unaffected controls (n=12, 0.010± 
0.003)(p<0.05)(Fig. 1)(Table 3).204  Psychiatry Investig 2010;7:202-207
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Correlation analysis
Spearman’s rank correlation test reveals that two markers in 
the hippocampus were significantly correlated (p<0.0001) with 
GSK-3β mRNA levels in the hippocampus (Figures 2 and 3). 
GSK-3β mRNA expression levels were significantly correlat-
ed with nitric oxide synthase 1 (NOS1)(ρ=0.70, p<0.0001) and 
stathmin-like 3 (STMN3)(ρ=0.70, p<0.0001) in the hippocam-
pus (Table 4). In the results of correlation analysis from 20 
MDD and unaffected control subjects, a similar correlation 
pattern was also found between GSK-3β, NOS1 and STMN3. 
However, the result was statistically significant only between 
GSK-3β and STMN3 (Table 5).
Effect of confounding variables
We could not find any significant association between GSK-
3β mRNA expression in the hippocampus and confounding 
variables (11 descriptive variables mentioned in the method 
part). However, we observed a weak correlation between GSK-
3β mRNA levels and PMI in the hippocampus (ρ=-0.30, p= 
0.0522). On the basis of ANCOVA with adjustment for age and 
PMI, a more marked statistical difference in GSK-3β mRNA le-
vel was identified between the MDD group and the control 
group, as p value of 0.003.
In order to statistically control for the general effects of age, 
sex, clinical diagnosis, brain pH and PMI, a partial correlation 
analysis was also performed. We also acquired significant re-
sults in the partial correlation analysis between GSK-3β, NOS1 
and STMN3 (Table 5).
DISCUSSION
The first objective of this study was achieved by identifying 
increased GSK-3β mRNA expression in the hippocampus in 
the MDD group as compared to the control group. This result 
corresponds with the results of previous studies which have 
suggested that GSK-3β activity (or level) is increased signifi-
cantly in the brain of patients with MDD.
5,6,8,9,11,12 This study 
indicated the hippocampus as the major region that is associ-
ated with increased GSK-3β activity in MDD among various 
brain regions.
The hippocampus has been known to be involved in the 
pathophysiology of MDD. A meta-analysis of 12 studies of 
Table 1. Result of exploring GSK-3β in all brain regions by using SNCID
Marker Researcher Brain/Region Experimental method Published
GSK-3β Belmaker, Robert Frontal Western blot Yes
GSK-3β Yoshikawa, Takeo Frontal (BA6) Western blot No
GSK-3β* Deakin, William Hippocampus qRT-PCR No
*data normalized to geometric mean of succinate dehydrogenase complex subunit A (SDHA) and beta actin (ACTB) amounts. GSK-3β: glyco-
gen synthase kinase-3β, SNCID: Stanley Neuropathology Consortium Integrative Database, qRT-PCR: quantitative reverse transcriptase poly-
merase chain reaction, BA: Brodmann area
Table 2.  Result of variance analysis of GSK-3β mRNA expression from hippocampus
Marker Brain region
BP, MDD, Schiz, control BP vs. control MDD vs. control Schiz vs. control
H p Subjects p Subjects p Subjects p
GSK-3β mRNA* Hippocampus 7.883 0.048 11 : 12 0.622 8 : 12 0.025 11 : 12 0.441
Statistical significance test was done by Kruskal-Wallis test or Mann-Whitney U-test. *data normalized to geometric mean SDHA and ACTB 



















Figure 1. Comparison of GSK-3β mRNA expression level in de-
pression group and control group (data normalized to geometric 
mean of SDHA and ACTB amounts). GSK-3β: glycogen synthase 
kinase-3β, mRNA: mesenger ribonucleic acid.
Table 3. Demographic and clinical characteristics of study subjects
MDD Unaffected controls
Age (year) 44.25±10.98 47.33±11.33
Sex 4F, 4M 6F, 6M
Race 8W 11W, 1NW
Duration of illness 10.56±8.38 0
Suicide 4 0
PMI (hour) 31.62±9.73 23.41±11.14
Brain pH 06.16±0.18 6.23±0.25
MDD: major depressive disorder, F: female, M: male, W: white, NW: 
non-white, PMI: postmortem intervalDH Oh et al. 
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MDD reported that hippocampal volume is reduced in pa-
tients with MDD, perhaps as a consequence of repeated peri-
ods of MDD.
15 However, the mechanism of the hippocampal 
volume reduction is still unknown. Based on our results and 
the report of Inkster et al.
10 we cautiously suggest that the ele-
vated GSK-3β level-inflicted neuronal cell death pathways may 
be associated with decreased hippocampal volume.
Although the mechanism by which overexpressed GSK-3β 
causes apoptosis has not been fully identified, GSK3 has been 
known to promote the intrinsic apoptotic signaling pathway 
by regulating transcription factors that control the expression 
of pro-apoptotic proteins (e.g., Bax, Bim) and anti-apoptotic 
proteins (e.g., Bcl-2, Mcl-1, Bcl-xL), by promoting microtu-
bule disruption and cell structural changes that occur during 
apoptosis, and by promoting disruption of mitochondria (e.g., 
cytochrome c).
16 As such, we have also attempted to find ex-
perimental data related to apoptotic signaling pathway asso-
ciated with increased GSK-3β expression in the hippocampus 
by using the SNCID. However, as we were unable to find rel-
evant data, we could not proceed with further analysis.
Our results also highlight correlations between GSK-3β, NOS1 
and STMN3 in the hippocampus. NOS1 produces NO in ner-
vous tissue in both the central and peripheral nervous system.
17 
Physiological amounts of NO are neuroprotective. If it is pro-
duced in excess, or if a cell is under conditions of oxidative st-
ress, NO becomes noxious and may undergo an oxidation-re-
duction reaction to form toxic compounds known as reactive 
nitrogen species (RNS), which cause cell damage. Both NO 
and RNS have a pathogenetic role in the onset and develop-
ment of neurodegenerative disorders.
18 A recent study found 
that hippocampal NOS1 over-expression and impaired neuro-
genesis were observed in the mice exposed to chronic mild st-
ress (CMS) that exhibited behavioral changes typical of de-
pression. The CMS-induced behavioral despair and hippocam-
Figure 2. Correlation between hippocampal GSK-3β & NOS1 level in all the subjects (N=42)(data normalized to geometric mean of SDHA and 
ACTB amounts). A: The expression level of GSK-3β mRNA was positively correlated with NOS1 mRNA expression level, and the Spearman's 





























































A   B  
Figure 3. Correlation between hippocampal GSK-3β & STMN3 level in all the subjects (N=42)(data normalized to geometric mean of SDHA and 
ACTB amounts). A: The expression level of GSK-3β mRNA was positively correlated with the STMN3 mRNA expression level, and the Spearman’s 
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Table 4. The results of correlation analysis
Marker Brain/Region Method ρ p-value
GSK-3β* Hippocampus qRT-PCR 1.000 0.000
NOS1* Hippocampus qRT-PCR 0.700 0.000
STMN3* Hippocampus qRT-PCR 0.700 0.000
*data normalized to geometric mean of SDHA and ACTB amounts. 
GSK-3β: glycogen synthase kinase-3β, NOS 1: nitric oxide synthase 1, 
STMN3: stathmin-like 3, qRT-PCR: quantitative reverse transcrip-
tase polymerase chain reaction, ρ: spearman rho correlation coeffi-
cient206  Psychiatry Investig 2010;7:202-207
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pal neurogenesis impairment were prevented and reversed in 
the null mutant mice lacking the NOS1 gene (NOS1-/-) and in 
the mice receiving NOS1 inhibitor.
19 Hippocampal NOS1 ex-
pression was also increased in the CA1 region of patients with 
major depression. This was significantly more marked in sam-
ples from the right hemisphere.
20
STMN3 belongs to the stathmin family. Stathmin is a mem-
ber of a novel class of microtubule-destabilizing proteins that 
regulate the dynamics of microtubule polymerization and de-
polymerization.
21 Stathmin is highly enriched in the lateral 
nucleus of amygdala, the main input of fearful information 
about the unconditioned stimuli and conditioned stimuli to 
the amygdala and the site of their convergence during fear 
learning. Amygdala-enriched stathmin is required for the ex-
pression of innate fear and the formation of memory for learn-
ed fear.
22 The role of stathmin in the human hippocampus is 
still unknown to us. However, in our study, we also found that 
the STMN3 mRNA expression level was slightly increased in 
the hippocampus of patients with major depression compared 
to normal controls, but there was no statistical significance 
observed between the two groups (p-value 0.069). Based on 
the results of previous research, we cautiously speculate that 
stathmin is involved in modulating hippocampal synaptic pl-
asticity in the pathogenic process of major depression.
In the previous research using postmortem brain tissue from 
SNC, the subjects with MDD had significantly lower hippo-
campal 5-HT1A mRNA expression compared with the normal 
control group.
23 Decreased 5HT1A and increased GSK-3β ex-
pression in the hippocampus of patients with MDD would be 
associated with the hypothesis that low 5HT1A activation may 
result in deficient inhibitory control of GSK-3β through im-
paired phosphorylation in the MDD.
Although this study provides interesting points for further 
exploration and evaluation, we believe that it should be con-
sidered exploratory at this stage. Future work will be needed to 
explore the biological pathway associated with increased GSK-
3β level and its function in the hippocampus of patients with 
MDD. Our study has also several limitations, mostly stemming 
from small sample size of the original data and preliminary 
exploratory study design using an online web-based database. 
In this study, we found significant correlation between GSK-
3β and other molecules. However, a correlation does not mean 
that one variable causes the other. In particular, the expres-
sion levels of many genes and some cytoarchitectural traits 
could be affected by confounding factors such as age, sex, brain 
pH, PMI, drug and alcohol histories in studies using human 
postmortem brain tissue.
24 A causal relationship between two 
variables should be cautiously interpreted.
Summing up, our results correspond with the results of pre-
vious animal study that reported increased GSK-3β mRNA 
expression in the hippocampus of those with depression. Our 
findings also suggest that oxidative stress-induced neuronal 
cell death, abnormal synaptic plasticity, and serotonergic dys-
regulation in the hippocampus may play important roles in the 
pathophysiology of major depression.
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